Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Sick from a nasty stomach bug? Moderna's Norovirus vaccine might be the solution
Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...
From Covid to Norovirus: Moderna’s mRNA Tech Takes on Stomach Flu
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
A Norovirus Vaccine May Be Coming
“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...
HealthDay on MSN3d
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine
The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.
Managed Healthcare Executive8d
Moderna Awarded $590 Million for Bird Flu Vaccine Development
The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...